Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficay of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma
|Effective start/end date
|11/27/18 → 5/6/22
- SOLIGENIX INC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.